Microbiota and Pancreatic Cancer Cachexia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGenton Graf Laurence
About this trial
This monocentric study aims at evaluating the effects of fecal microbiota transplantation from newly diagnosed cachectic and non-cachectic pancreatic cancer patients, and healthy volunteers on several cachexia-related parameters of germ-free mice.
Eligibility criteria
Qualifiers
≥18 years and
Newly diagnosed of pancreatic adenocarcinoma (local or metastatic) and
Tube feeding or parenteral nutrition ≤ 14 days
Cachexia according to the Fearon criteria 1: involuntary weight loss >5% over the last 6 months, or any level of weight loss >2% and a BMI <20 kg/m2 or sarcopenia. Sarcopenia will be diagnosed by BIA (fat-free mass index is <17 kg/m2 in men and <15 kg/m2 in women) 81, and not by CT, as it is faster and can be performed at the bedside of the patient. Non-cachectic pancreatic cancer patients (n=6)
Disqualifiers
< 18 years or
Inability to give consent or
Insufficient knowledge of project language (French, German) or
Pancreatic adenocarcinoma already treated by chemo- or radiotherapy, or major surgery as duodenopancreatectomy or biliary diversion
Trial design
Treatments tested in this trial
- Not listed
Trial groups
24 Participants
are grouped into 3 trial groupsSponsors and collaborators
Genton Graf Laurence
Lead sponsor
University Hospital, Geneva
Sponsor institution
Source ClinicalTrials.gov